Summary & Overview
HCPCS A9564: Chromic Phosphate P-32 Suspension, Therapeutic
HCPCS Level II code A9564 designates chromic phosphate p-32 suspension billed per millicurie for therapeutic use. This radiopharmaceutical is used in localized intracavitary or targeted radiation therapy and is relevant for oncology and nuclear medicine service lines. Nationally, accurate coding for radiotherapeutics affects access to specialty treatments, facility billing workflows, and payer policy alignment for high-cost, regulated radioactive agents. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of clinical context for chromic phosphate p-32 suspension, typical sites of service, and common billing considerations. The publication summarizes payer coverage patterns and benchmark considerations where available, highlights policy updates that affect radiopharmaceutical reimbursement, and clarifies billing constructs tied to per-millicurie dosing. It also points to practical implications for facility coding and claims submission, and outlines areas where additional clinical or coding documentation is commonly required. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code A9564 describes chromic phosphate p-32 suspension, therapeutic, per millicurie. This entry represents a radiopharmaceutical therapeutic agent supplied as a suspension of phosphorus-32 used for intracavitary or localized radiotherapy.
-
Service type: Therapeutic radiopharmaceutical administration of a radioactive suspension measured per millicurie
-
Typical site of service: Hospital outpatient departments, specialty infusion centers, or nuclear medicine facilities where therapeutic radiopharmaceuticals are administered
Clinical & Coding Specifications
Clinical Context
A patient with refractory localized or diffuse synovitis, malignant pleural effusion, or certain hematologic malignancies is referred to an interventional oncology or nuclear medicine service for intralesional or intrapleural radiopharmaceutical therapy. The clinician prescribes A9564 (chromic phosphate P-32 suspension) measured in millicuries based on disease extent and prior treatments. Typical workflow: the patient is evaluated in outpatient oncology or hospital oncology clinic; informed consent and radiation safety counseling are completed; baseline labs and imaging (e.g., ultrasound, CT) are reviewed; a radiation safety officer verifies activity and prepares the P-32 dose in a licensed radiopharmacy; the patient is brought to a procedure room or nuclear medicine suite; under image guidance or direct instillation, the clinician administers the P-32 suspension into the target cavity (for example, the pleural space) or lesion; post-procedure monitoring is performed for immediate complications; discharge instructions include radiation precautions and follow-up imaging to assess response. Typical site of service: hospital outpatient department, inpatient hospital bed (for hospitalized patients), or specialized nuclear medicine/interventional oncology clinic. Typical patient scenario: a 68-year-old with recurrent malignant pleural effusion from metastatic lung adenocarcinoma undergoes thoracoscopic drainage and intrapleural instillation of A9564 to reduce recurrent effusion and palliative symptoms.
Coding Specifications
| Modifier | Description |
|---|